RIPK2 inhibitors have shown benefit in inflammatory disease including in the SAMP1/YitFc model of Crohn’s disease-like ileitis (177–179) although there are no clinical studies as yet in intestinal inflammation. Here, RIPK2 is linked to Crohn disease.